VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

VERAXA Biotech reported first in vivo proof-of-concept for its BiTAC®-ADC, citing tumor-selective activation, potent anti-tumor efficacy and improved safety. The brief announcement provides no quantitative results or details on study stage, so the findings indicate early promise rather than established clinical benefit.